Volume 42, Issue 18, Page 8 (15 October 2009)
10 of 55
PREVIEW
FULL TEXT
FULL-TEXT PDF (98 KB)
CITATION ALERT
CITED BY
RELATED ARTICLES
EXPORT CITATION
EMAIL TO A COLLEAGUE
RIGHTS/PERMISSIONS
NEED REPRINTS?
BOOKMARK ARTICLE
The Food and Drug Adminstration approved guanfacine (Intuniv) for treatment of attention-deficit/hyperactivity disorder for children and adolescents aged 6-17 years.
PII: S1097-8690(09)70713-9
© 2009 Elsevier Inc. All rights reserved.
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
PREVIEW